

AREV LIFE SCIENCES GLOBAL CORP.
PRESS RELEASE

**AREV Life Sciences enters Into Collaboration Agreement with
Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba**

VANCOUVER, BC / March 10, 2022 / AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) AREV Life Sciences announced today it has engaged the University of Manitoba, Richardson Centre for Functional Foods and Nutraceuticals to complete the design and produce the prototypes of its Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs “SUSTAINN”, AREV’s next generation Ready to Use Therapeutic Food (RUTF.)

AREV, through its US subsidiary in Rochester NY, is developing the next generation, aflatoxin free RUTF for the treatment of SAM leading to inanition. AREV’s SUSATAINN is being developed in collaboration with representatives of several academic research institutions, including the Institute for Human Virology (IHV), The Linus Pauling Institute (LPI) at Oregon State University (OSU) and the Richardson Centre for Functional Foods and Nutraceuticals “RCFFN” at the University of Manitoba.

The agreement dated, March 2, 2022, for RCFFN to assist in the design and formulation of a next generation truly therapeutic Ready to Use Therapeutic Food “RUTF”. The project will be composed in two stages:

1. To research and propose 3 RUTF formulations for the client to consider, factoring in optimal amino acid content, fibre, fat, taste, cost and caloric build.
2. Once a RUTF is selected, RCFFN will prepare small batches of the RUTF in the RCFFN Commercial Kitchen.

AREV’s SUSTAINN addresses the clinical causes of SAM and inanition which facilitate disease progression including dysbiosis, environmental enteropathy, elevated inflammation, and immune dysfunction that are associated with increased morbidity and mortality in key populations affected by disease progression as substantiated in multiple peer-review publications. SUSTAINN is being developed to meet and exceed guidance set forth by public health commodity procurement programs such as USAID and UNICEF. The design is in accordance with the World Health Organization (WHO) Global Action Plan (GAP) for Child Wasting Guidelines published March 2021 and the UNICEF RUTF Procurement Guidance, published April 2021. The information in the WHO and UNICEF guidelines support the UN Millennium Development Goals (MDG’s) identified at the 2021 Nutrition for Growth (N4G), summit held in Tokyo, which demonstrates definitive clinical affect with attribution of mechanisms of action for a diverse cost-effective intervention in patient populations in low- and middle-income countries dependent on global health commodity distribution through implementing Non-Government Organizations (NGO).

“AREV’s development of SUSATAINN is now being enhanced by this collaboration with the Richardson Centre for Functional Foods and Nutraceuticals at the University of Manitoba ”said Dr. Roscoe Moore, Chairman of the Scientific Advisory Board for AREV Life Sciences, and Board Member of Global Virus Network. He went on to say, “Our product development and research from Linus Pauling Institute has provided the initial data to be applied with the scientists at The Richardson Centre for Functional Foods and Nutraceuticals in order to accelerate the introduction of SUSTAINN into public health commodity procurement program utilization to combat global famine and serious and acute malnutrition during the intersection of COVID-19 and other pandemic infections that are driving a global decline of life expectancy and childhood mortality.”

“We are excited to collaborate with AREV Life Sciences on this innovative product development project benefiting global public health. The development of SUSTAINN as a healthy, nourishing RUTF at a low-cost has the potential to bring significant nutritional value to populations experiencing famine.” stated Michael Janzen, PhD, Research Development Manager, University of Manitoba, Richardson Centre for Functional Foods and Nutraceuticals.

The invasion of Ukraine comes at a time when the complete collapse of food security in Ethiopia, (Source <https://www.mercycorps.org/blog/fighting-hunger-ethiopia>) Venezuela (Source <https://www.frontiersin.org/articles/10.3389/fsufs.2021.635981/full>) and Afghanistan (source <https://www.orfonline.org/research/the-crisis-of-food-insecurity-in-afghanistan/>) places tens of millions at further risk of malnutrition and starvation. The recent introduction of the Global Malnutrition Prevention and Treatment Act (S.2956/H.R.4693), led by Senators Christopher Coons (D-DE), and Representative Gregory Meeks (D-NY) Chair of the House Committee for Foreign Affairs and USAID, America's international development agency, to support countries to address global famine by increasing coverage for high impact, proven and affordable interventions, including research on next generation therapeutic foods to treat severe acute malnutrition (SAM) that now is the leading cause of death of children worldwide and accounting for more than three million deaths annually and expected to exponentially increase in 2022. AREV's collaboration with the RCFFN accelerates bringing SUSTAINN to the marketplace and in conjunction with other efforts by our academic partners so AREV can clearly demonstrate the clinical efficacy of our next generation RUTF.

More than two million people from Ukraine are now refugees and the UN is predicting 5 to 6 million more Ukrainians to flee as the conflict escalates, (source <https://www.bbc.com/news/world-60555472>) the majority being women and children to enter in neighbouring EU countries which have committed to unprecedented levels of humanitarian assistance for both refugees as well as those besieged in the conflict zone within the first week of the conflict. More than half of the one million Ukrainian refugees are children, according to Philippe Cori, UNICEF's Deputy Regional Director for Europe and Central Asia. Those leaving Ukraine are mostly women and children. "The situation for children in Ukraine is getting worse by the minute. Children are being killed and injured. 7.5 million children are at risk," Cori warned at a press conference in Paris on Thursday (3 March).

The Eleanor Crook Foundation, a recognized global policy leader in malnutrition and famine is on the record for their analysis of the current policies exacerbating the global famine "The scale of the problem is immense, but proven interventions to prevent and treat malnutrition are considered some of the most cost-effective solutions in global health and development." (source <https://eleanorcrookfoundation.org/>).

In a United Nations published report dated November 2021 on Global Action Plan (GAP) for Child Wasting (source <https://www.childwasting.org/>). Key priority food action includes, strict quality assurance (QA) standards. Guarantee the safety and quality standards of locally produced specialized nutritious foods necessary for the treatment of child wasting. This can be achieved through better collaboration with the private sector and support efforts to prevent and reduce aflatoxin and other toxins in therapeutic foods.

For further information, contact Mike Withrow, arevlifesciences@gmail.com 778-929-6536. For more information visit www.arevlifesciences.com.

On behalf of the Board,

Mike Withrow
CEO & Director

ABOUT AREV Life Sciences Global Corp.

AREV Life Sciences Global Corp. is a fully integrated, publicly traded, early-stage life science enterprise, with a US subsidiary dedicated to delivering therapeutic interventions to public health through extraction of unique compounds, discovery, innovation and successful collaborations. The company's leadership drives discovery programs for clinical complexities

presented by malnutrition, viral infectious diseases, and elevated inflammatory responses. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic co-morbidities and innovations human nutrition. AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTEC Canada and The Biotechnology Innovation Organization (BIO).

About The Richardson Centre for Functional Foods and Nutraceuticals (RCFFN), University of Manitoba

RCFFN is a state of the art, academic institution collaborating with private industry and government initiatives to drive innovation throughout the human nutrition global private sector. RCFFN connects researchers with the food and agriculture value chain by engaging in collaborative pre-commercial product activities. The RCFFN is uniquely positioned to offer the expertise of internationally recognized researchers in the University of Manitoba Department of Food and Human Nutrition Sciences and includes 55,000 square feet of state of the art analytical, extraction, processing, cell and human nutrition testing laboratories. More about the Richardson Centre for Functional Foods and Nutraceuticals can be found at <https://umanitoba.ca/richardson-centre-for-functional-foods/>.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com.